Amendments to the Claims:

Please amend claims 8 and 16.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-7. (Cancelled)

8. (Currently Amended) A method for inhibiting LPAAT-β (lysophosphatidic acid acyltransferase β) comprising contacting LPAAT-β with an effective amount of a compound of the Formula:



wherein,

R^1 is halo, hydroxy, alkylmercapto, mercapto, alkoxy, aryloxy or ~~substituted amino~~-NRR wherein each R group is independently selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, or the R groups are joined together to form a heterocyclic ring with the N;

R^2, R^3, R^4 and R^5, each of which may be same or different, are hydrogen, alkyl, substituted alkyl, alkenyl, alkynyl, aryl or ~~substituted~~ aryl substituted with 1 to 3 substituents selected from hydroxy, alkoxy and halogen; or

R^2 and R^3 or R^4 and R^5, together with the nitrogen to which they are attached, form a piperidine, piperazine, or a morpholine ring; or

pharmaceutically acceptable salt thereof;

thereby inhibiting LPAAT-β.

9. (Original) The method of claim 8, wherein said LPAAT-β is found in an animal.

10. (Original) The method of claim 9, wherein said animal is a mammal.

11. (Original) The method of claim 10, wherein said mammal is a human.

12. (Previously Presented) The method of claim 8, wherein R^1 is chloro, R^2 and R^4 are hydrogen and R^3 and R^5 are phenyl; or

pharmaceutically acceptable salt thereof.

13. (Previously Presented) The method of claim 8, wherein R^1 is chloro, R^2 and R^4 are hydrogen, R^3 is phenyl and R^5 is 4-chlorophenyl; or

pharmaceutically acceptable salt thereof.

14. (Previously Presented) The method of claim 8, wherein R^1 is chloro, R^2 and R^4 are hydrogen, R^3 is t-butyl and R^5 is 4-chlorophenyl; or

pharmaceutically acceptable salt thereof.

15. (Previously Presented) The method of claim 8, wherein R^1 is chloro, R^2 and R^4 are hydrogen, R^3 is 4-methoxyphenyl and R^5 is 4-chlorophenyl; or

pharmaceutically acceptable salt thereof.

16. (Currently Amended) The method of claim 8, wherein the compound is selected from the group consisting of ~~6-chloro-N-(4-methoxy-phenyl)-N'-p-tolyl-[1,3,5]triazine-2,4-diamine,~~ N-butyl-6-chloro-N'-(4-chlorophenyl)-[1,3,5]triazine-2,4-diamine, ~~6-chloro-N-isopropyl-N'-p-tolyl-[1,3,5]triazine-2,4-diamine,~~ N-tert-butyl-6-chloro-N'-phenyl-[1,3,5]triazine-2,4-diamine, (4-chloro-6-morpholin-4-yl-[1,3,5]triazin-2-yl)-naphthalen-1-yl-amine, ~~N-tert-butyl-6-chloro-N'-p-tolyl-[1,3,5]triazine-2,4-diamine,~~ 6-chloro-N-cyclo-hexyl-N'-isopropyl-[1,3,5]triazine-2,4-diamine, 2-(4-chloro-6-phenylamino-[1,3,5]triazin-2-ylamino)-2-methyl-propan-1-ol, 6-chloro-N-isopropyl-N'-phenyl-[1,3,5]triazine-2,4-diamine, 6-chloro-N-(4-chloro-phenyl)-N'-cyclohexyl-[1,3,5]triazine-2,4-diamine, N-allyl-6-chloro-N'-cyclohexyl-[1,3,5]triazine-2,4-diamine, 2-(4-chloro-6-phenylamino-[1,3,5]triazin-2-ylamino)-ethanol, N-tert-butyl-6-chloro-N'-cyclopentyl-[1,3,5]triazine-2,4-diamine, 6-chloro-N-(4-methoxyphenyl)-N'-phenyl-[1,3,5]triazine-2,4-diamine, N-benzo[1,3]dioxol-5-yl-6-chloro-N'-(4-chlorophenyl)-[1,3,5]triazine-2,4-diamine, 6-chloro-N-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-N'-phenyl-[1,3,5]triazine-2,4-diamine, N-benzo[1,3]dioxol-5-yl-6-chloro-N'-phenyl-[1,3,5]triazine-2,4-diamine, 6-chloro-N-indan-5-yl-N'-phenyl-[1,3,5]triazine-2,4-diamine, 6-chloro-N-(4-chloro-phenyl)-N'-propyl-[1,3,5]triazine-2,4-diamine, N-(4-chloro-phenyl)-6-methoxy-N'-propyl-[1,3,5]triazine-2,4-diamine and N-(4-chloro-phenyl)-6-methylmercapto-N'-phenyl-[1,3,5]triazine-2,4-diamine.

17.-39. (Cancelled)